Gabrielsen Discusses New State and Federal Efforts to Curb Prescription Opioid Abuse
08 February 2018
Associate Lindsey Gabrielsen is quoted in a Bloomberg BNA Health Law Resource Center article, “Doctors Feel the Pinch of Anti-Opioid Efforts,” about doctors’ efforts to comply with new state and federal limits on prescribing opioids.
Gabrielsen said the new limits can trip up physicians who don’t keep careful track of their prescribing history. “These government initiatives use data mining and data sharing to identify and target those physicians who prescribe more opioids than their peers, making them potential targets for government investigation,” she said.
She said doctors can take a number of practical steps to manage their opioid prescription risks, including taking the time to understand their state’s opioid prescribing laws. Focusing on documentation compliance is critical, she added. “If the government issues an investigatory subpoena for records, prescribers must be able to produce complete patient records containing notes with patient history, examination, and prescription information,” she said.
Gabrielsen said the new limits can trip up physicians who don’t keep careful track of their prescribing history. “These government initiatives use data mining and data sharing to identify and target those physicians who prescribe more opioids than their peers, making them potential targets for government investigation,” she said.
She said doctors can take a number of practical steps to manage their opioid prescription risks, including taking the time to understand their state’s opioid prescribing laws. Focusing on documentation compliance is critical, she added. “If the government issues an investigatory subpoena for records, prescribers must be able to produce complete patient records containing notes with patient history, examination, and prescription information,” she said.
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”